In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e16029-e16029
Abstract:
e16029 Background: Combination of platinum/5-FU and cetuximab is a 1st line standard treatment approach for R/M SCCHN. Results of a phase II study (Ann Oncol Aug 23, 2011) have shown an encouraging activity and tolerability of the combination of CTX and weekly PTX in this setting suggesting an alternative for unfit patients (pts) or when platinum-based chemotherapy is contraindicated. Methods: A retrospective analysis of our database was performed to evaluate outcomes in pts with R/M SSCHN who were treated under compassionate use with weekly PTX (80 mg/m 2 IV) and CTX (initially 400 mg/m 2 followed by 250 mg/m 2 ) until progression or intolerance in a single institution in Madrid (Spain) between November, 2008 and July, 2011. Results: 16 pts were included (73% male) with a mean age of 58 years. Mainly squamous carcinomas: pharynx (7), larynx (2), tonsil (2), tongue (3), paranasal sinuses (1) and cavum lymphoepithelioma (1). Twenty percent of the pts received this treatment in 1st line; 67% in 2nd line treatment and only 2 pts received it as 3rd line treatment. Out of those who received PTX-CTX as 2nd or 3rd line treatment, 40% had received CTX as part of the 1st line treatment. Pts received a median of 13.87 cycles. All pts were evaluable for response and toxicity. Disease control rate was 47% (7% CR, 27% PR and 13% SD). With a median follow up of 10.3 months the median PFS was 4.7 months. PFS was 5.2 months for 1st line and 4 months for 2nd line after CTX. Acne-like rash appeared in 100% of the pts. It was G 1-2 in 87% of the pts and G 4 only in one patient, forcing to discontinue CTX. Main related toxicities (G 2-3) were diarrhea (13.34%) and hand-foot syndrome (13.33%). Hematological toxicity was mild, more remarkable in 3rd line treatment, and being managed with dose delays and, in two cases, with a 20% reduction of the PTX dose. Conclusions: The combination of cetuximab and weekly paclitaxel was active, well tolerated and manageable. It may be a first-line option for pts with poor performance status or non eligible for platinum as well as second line treatment for those who have failed first line platinum +/- cetuximab containing chemotherapy.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e16029
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
detail.hit.zdb_id:
604914-X
Permalink